QNCX · Quince Therapeutics, Inc.
$33.75
+1.25 (+3.85%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$35.29M
Shares
1.02M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-12-18 | 2025-10 | $75,000,000 | $47,500,000 as of 2026-06-30 | — | 10-Q , filed 2026-08-14 |
Key facts
CIK
1662774
CUSIP
22053A305
13F (30d)
32 filings
28 filers
Visit website
Investor relations